A phase II trial of arsenic trioxide (NSC #706363) for relapsed or refractory acute lymphoblastic leukemia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 21 Jun 2013 Biomarkers information updated
- 11 Jan 2007 Status changed from in progress to completed
- 27 Sep 2005 New trial record.